Vantage Point

Our latest thinking on biopharmaceutical development and commercialization.


Using registries to support HTA submissions in Japan
Health Technology Assessment (HTA) is becoming an essential part of market access across the globe — and Japan is no exception.

Quintiles Blog

Fresh ideas and insights from our experts around the globe


Topics to Explore


Biosimilar development and commercialization is a uniquely difficult endeavor requiring precise, stepwise planning to ensure timely regulatory approval and optimal market access. 

Data & Technology

To turn data into insights, upgraded IT systems are essential. Outdated systems lead to significant costs – in terms of time, frustration and an increased risk of errors. Integrated IT systems are a crucial component in reducing manual processes, resulting in fewer errors, faster processes, far less frustration and ultimately lowering your costs. Benefit from more insightful data analysis, which can lead to groundbreaking discoveries.


As the prevalence of diabetes continues to increase globally, and the market for new therapies grows increasingly crowded, it's more important than ever to match the right drug to the right patient.

Evidence & Value

Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments.

Rare Diseases

3+ years looking for treatment

Although regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly payers are making hard choices about reimbursing these therapies.

Peer-Reviewed Publications
Blood Pressure Measurement Modalities: A Primer for Busy Practitioners.
J Clin Hypertens (Greenwich). 2015 Nov 12.
Read more
An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Int J Antimicrob Agents. 2015 Oct 22. pii: S0924-8579(15)00330-1.
Read more
Translational Medicine and Patient Safety in Europe: TRANSFoRm-Architecture for the Learning Health System in Europe.
Biomed Res Int. 2015;2015:961526.
Read more
Practice Innovations, Change Management, and Resilience in Oncology Care Settings.
Oncol Nurs Forum. 2015 Nov 1;42(6):683-7.
Read more
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Clin Ther. 2015 Oct 26. pii: S0149-2918(15)01149-2.
Read more